ClinicalTrials.gg
Not yet recruitingNCT07746089CoMetSUpdated Oct 19, 2026

A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)

A Phase 3 interventional study of Adimanebart IV and Placebo IV in Congenital Myasthenic Syndrome and CMS, sponsored by argenx. Not yet recruiting. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by argenx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess efficacy and safety of adimanebart in participants at least 12 years of age with DOK7-, MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS). The study aims to determine whether adimanebart is safe and can help people with CMS feel better and perform daily activities more easily.

The study includes a double-blinded treatment period (DBTP) and an Open- label extension period (OLE). In the DBTP, all participants will be randomized in a 1:1 ratio to adimanebart or placebo. Participants who complete the DBTP will continue to the OLE.

Additionally, participants who complete part of the active-treatment period of ARGX-119-2302 study are eligible to enroll in the OLE of this study. In the OLE, all participants will receive open-label adimanebart. After final IMP dose, the participants will enter a follow-up period and their health will be monitored.

The total duration of the study is up to approximately 152 weeks (2 years and 11 months).

More information can be found here: clinicaltrials.argenx.com/comets

02

Conditions studied

  • Congenital Myasthenic Syndrome
  • CMS
03

In context

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

DBTP:

  • At least 12 years of age.
  • Has a diagnosis of DOK7-, MUSK-, AGRN-, or LRP4-CMS with documented mutations.
  • Participants taking oral beta agonists (eg, albuterol, salbutamol, ephedrine) or other CMS medication must have been receiving the medication for at least 6 months and agree to remain on a same stable dosing regimen of the same medication unless directed to change their CMS medication(s) by their treating physician.

OLE:

  • Completed part of the active-treatment period of ARGX-119-2302.

Exclusion criteria

Exclusion Criteria:

DBTP:

  • Known medical condition that would interfere with an accurate assessment of CMS, confound the results of the study, or put the patient at undue risk, as assessed by the investigator.

OLE:

  • study drug discontinuation in ARGX-119-2302.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Double-blinded treatment period (DBTP) - Adimanebart IV

    Participants randomized to receive Adimanebart IV

    Biological: Adimanebart IV

  • Placebo comparator
    Double-blinded treatment period (DBTP) - Placebo IV

    Participants randomized to receive Placebo IV

    Other: Placebo IV

  • Experimental
    Open-label extension (OLE) - Adimanebart IV

    Participants receive Adimanebart IV

    Biological: Adimanebart IV

Interventions

  • BiologicalAdimanebart IV

    Intravenous infusion of Adimanebart

  • OtherPlacebo IV

    Intravenous infusion of Placebo

06

What researchers measure

Primary outcomes

  1. Change from baseline at week 24 in 6MWT distance

    The 6-minute walk test (6MWT) measures the distance a participant walks in 6 minutes.

    Time frame: Up to 24 weeks

  2. Incidence of AEs and SAEs

    AE: adverse event; SAE: serious adverse event

    Time frame: up to 104 weeks

Secondary outcomes

  1. Change from baseline in 6MWT distance over time

    The 6-minute walk test (6MWT) measures the distance a participant walks in 6 minutes.

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

  2. Change from baseline in PROMIS PF-10b T-score over time

    The PROMIS PF-10b T-score (Patient-Reported Outcomes Measurement Information System Physical Function 10b) is a 10- item, participant-reported short-form questionnaire designed to assess physical function. The questionnaire asks the participant to rate the items on a 5-point Likert scale of 5 (without any difficulty) to 1 (unable to do)

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

  3. Change from baseline in QMG key component composite score over time

    The Quantitative Myasthenia Gravis (QMG) scale is a standardized quantitative scoring system that was developed to assess disease severity based on impairment of body function and structures in patients with MG. Minimum value: 0 (no disease severity); Maximum value: 15 (highest disease severity).

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

  4. Change from baseline in 6MWT cadence over time

    The 6-minute walk test (6MWT) measures the distance a participant walks in 6 minutes. Cadence is the number of steps taken per unit of time (steps/min) and is a measure of functional mobility.

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

  5. Change from baseline in the QMG key component raw values and scores over time

    The Quantitative Myasthenia Gravis (QMG) scale is a standardized quantitative scoring system that was developed to assess disease severity based on impairment of body function and structures in patients with MG. Minimum value: 0 (no disease severity); Maximum value: 15 (highest disease severity).

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

  6. Change from baseline in PROMIS PF-WMA-SF T-score over time

    The PROMIS PF-WMA-SF T-score (Patient-Reported Outcomes Measurement Information System Physical Function With Mobility Aid Short Form) is an 11-item, participant-completed questionnaire that assesses lower and upper extremity function and associated activities of daily living. The questionnaire asks the participant to rate the items on a 5-point scale of 5 (without any difficulty) to 1 (unable to do).

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

  7. Change from baseline in Neuro-QoL Short Form-Fatigue T-score over time

    Neuro-QoL Short Form-Fatigue (Quality of Life in Neurological Disorders Short Form - Fatigue) is a participant-completed short-form questionnaire designed to provide a measurement of fatigue in patients with neurological conditions and the impact of their fatigue on their quality of life and daily activities.

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

  8. Change from baseline in FVC over time

    FVC: forced vital capacity to assess pulmonary function

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

  9. Change from baseline in the Actigraphy measures over time

    Participants will be asked to wear a wrist-worn actigraphy device to assess physical behaviour and mobility.

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

  10. Change from baseline in PGI-C over time

    The Patient Global Impression of Change (PGI-C) is a patient-reported rating scale to assess the change in symptom severity and functional problems since the first IMP administration. Participants are asked to rate their change in symptom severity and functional problems on a 7- point Likert scale from 1 (much improved) to 7 (much worse).

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

  11. Change from baseline in PGI-S over time

    The Patient Global Impression of Severity (PGI-S) scale is a patient-reported rating scale to assess symptom severity and functional problems. Participants are asked to rate their symptom severity and functional problems on a 7-point Likert scale from 1 (no problems) to 7 (unable to do).

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

  12. Change from baseline in CGI-C over time

    The Clinical Global Impression of Change (CGI-C) scale is a clinician-reported rating scale to assess changes in a participant's symptom severity and functional problems since the first IMP administration. Clinicians are asked to rate the change in the participant's symptom severity and functional problems on a 7-point Likert scale from 1 (much improved) to 7 (much worse)

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

  13. Change from baseline in CGI-S over time

    The Clinical Global Impression of Severity (CGI-S scale) is a clinician-reported rating scale to assess a participant's symptom severity and functional problems. The scale comprises a single item. Based on clinical judgment, clinicians rate the participant's symptom severity and functional problems on a 4-point Likert scale from 0 (no problems) to 4 (unable to do).

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

  14. Change from baseline in EQ-5D-5L over time

    The participant-completed EQ-5D-5L questionnaire is a standardized test recognized by many health authorities as a generic measure of health status.

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

  15. Incidence of AEs and SAEs

    AE: adverse event; SAE: serious adverse event

    Time frame: up to 24 weeks

  16. Adimanebart serum concentrations over time

    PK=pharmacokinetic(s)

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

  17. Incidence of ADA against adimanebart

    ADA: Anti-drug antibodies

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

  18. Incidence of NAb against adimanebart

    Nab: neutralizing antibody(ies)

    Time frame: up to 24 weeks (DBTP) + up to 104 weeks (OLE)

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Oct 2030, 49 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2026
First posted
Aug 4, 2026
StartEst.
Sep 2026
Primary completionEst.
Oct 2030
CompletionEst.
Oct 2030
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date, description and references
1 update, last Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Minor edits only
    + 4 other changes: identifiers, verification date, description and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07746089
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Aug 4, 2026
Start date
Sep 2026 (estimated)
Primary completion
Oct 2030 (estimated)
Completion
Oct 2030 (estimated)
Last update
Oct 19, 2026

Study contacts

Sabine Coppieters, MD
Contact
clinicaltrials@argenx.com
857-350-4834

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adimanebart

Start the discussion